Compare Agilysys Inc (AGYS) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilysys Inc vs Cytokinetics Inc — how do they compare? Agilysys Inc trades at $105 (market cap $3.18B), while Cytokinetics Inc trades at $84.75 (market cap $11.62B). The key difference: Cytokinetics Inc is far larger — about 3.7× Agilysys Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.
| AGYS | CYTK | |
|---|---|---|
Market Cap | $3.18B | $11.62B |
Sector | Technology | Technology |
52-Week High | $141.12 | $87.26 |
52-Week Low | $62.19 | $33.23 |
Enterprise Value | $3.08B | $12.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.
The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.
CYTK trades at $85.57, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported a net loss of $784.96 million in 2025, with revenue of $88.04 million, but recent news highlights the European launch of MYQORZO and upcoming clinical data presentations at the ESC Congress 2026, indicating growth potential.
The outlook for CYTK is driven by product launches and clinical milestones, but high valuation (P/S 98.09) and persistent losses pose risks. Analyst consensus is overwhelmingly bullish with a $110.60 price target, though investors must weigh the speculative nature against execution risks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
